SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1) *
Osteotech, Inc.
(Name of Issuer)
Common Stock, Par Value $.01
(Title of Class of Securities)
688582105
(CUSIP Number)
Arthur Goetchius
300 Park Avenue, 21st Fl., New York, NY 10022 (212) 755-9395
(Name, address and telephone number of person
authorized to receive notices and communications)
May 31, 1996
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition which is the subject of
this Schedule 13D, and is filing this schedule because of Rule
13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the
statement [ ]. (A fee is not required only if the reporting
person: (1) has a previous statement on file reporting
beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent
or less of such class.) (See Rule 13d-7.)
NOTE: Six copies of this statement, including all
exhibits, should be filed with the Commission. See Rule 13d-1(a)
for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934 ("Act") or otherwise subject
to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the
Notes).
PAGE 1 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
EGS Associates, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
54,292
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
54,292
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
54,292
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
.70%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 2 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
EGS Partners, L.L.C.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
197,149
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
197,149
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
197,149
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
2.54%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IA
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 3 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Bev Partners, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
32,167
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
32,167
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
32,167
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
.42%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 4 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
The Pharmaceutical/Medical Technology Fund, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
79,760
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
79,760
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
79,760
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
1.03%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 5 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Jonas Partners, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
24,480
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
24,480
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
24,480
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
.32%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 6 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
FK Trading Partners, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
19,862
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
19,862
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
19,862
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
.26%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 7 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
William Ehrman
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF OO
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
407,710
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
407,710
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
-0-
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
5.26%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 8 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Frederic Greenberg
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF PF OO
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
412,710
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
412,710
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
412,710
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
5.33%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 9 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Frederick Ketcher
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF PF OO
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
5,000
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
407,710
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
5,000
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
407,710
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
412,710
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
5.33%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 10 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Jonas Gerstl
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF OO
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
407,710
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
407,710
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
407,710
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
5.26%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 11 OF 22 PAGES
<PAGE>
13D
CUSIP No. 688582105
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
James McLaren
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF OO
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
407,710
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
407,710
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
407,710
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
5.26%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
PAGE 12 OF 22 PAGES
<PAGE>
The initial Schedule 13D (the "Schedule 13D"), of (i) EGS
Associates, L.P., a Delaware limited partnership ("EGS
Associates"), (ii) EGS Partners, L.L.C., a Delaware limited
liability company and a registered investment adviser ("EGS
Partners"), (iii) Bev Partners, L.P., a Delaware limited
partnership ("Bev Partners"), (iv) Pharmaceutical/Medical
Technology Fund, L.P., a Delaware limited partnership ("Pharm
Fund"), (v) Jonas Partners, L.P., a Delaware limited partnership
("Jonas Partners"), (vi) FK Trading Partners, L.P., a Delaware
limited partnership ("FK Trading"), (vii) William Ehrman, (viii)
Frederic Greenberg, (ix) Frederick Ketcher, (x) Jonas Gerstl,
and (xi) James McLaren, relating to the common stock, par value
$.01 per share (the "Common Stock"), issued by Osteotech, Inc.
(the "Company"), is hereby amended and restated by this Amendment
No. 1 as follows:
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The net investment cost (including commissions, if any) of
the shares of Common Stock beneficially owned by EGS Associates,
EGS Partners (exclusive of shares beneficially owned by EGS
Overseas), Bev Partners, Pharm Fund, Jonas Partners, and FK
Trading is approximately $301,004, $1,099,583, $178,653,
$424,651, $134,886, and $110,035, respectively.
The net investment cost (excluding commissions, if any) of
the shares of Common Stock owned directly by a member of Mr.
Greenberg's immediate family is approximately $25,000.
The net investment cost (excluding commissions, if any) of
the shares of Common Stock owned directly by Mr. Ketcher is
approximately $27,175.
Messrs. Ehrman, Gerstl and McLaren currently own no shares
of Common Stock.
The shares of Common Stock purchased by each of EGS
Associates, EGS Overseas,
Bev Partners, Pharm Fund, Jonas Partners and FK Trading were
purchased with the investment capital of the respective entities
and the shares of Common Stock purchased by EGS Partners were
purchased with investment capital of each discretionary account
under management of EGS Partners. The shares of Common Stock
purchased by Messrs. Greenberg and Ketcher were purchased with
personal funds.
The shares of Common Stock beneficially owned by EGS
Associates, EGS Partners (excluding EGS Overseas), EGS Overseas,
Bev Partners, Pharm Fund, Jonas Partners, and FK Trading are held
in their respective commingled margin accounts, or in the case of
EGS Partners, in margin and non-margin accounts held by each
discretionary account under its management. Such margin accounts
are maintained at Bear Stearns & Co. Inc., and may from time to
time have debit balances. Since other securities are held in such
margin accounts, it is not possible to determine the amounts, if
any, of margin used with respect to the shares of Common Stock
purchased. Non-margin accounts are maintained at Bankers Trust
Company and The Chase Manhattan Bank, N.A. The shares owned by
Mr. Greenberg are held in an account maintained at Goldman, Sachs
& Co. or are beneficially owned by a member of his immediate
family. The shares owned by Mr. Ketcher are held in his various
accounts maintained at Bear Stearns & Co. Inc. Currently, the
interest rate charged on such various margin accounts is
approximately 5.75% per annum.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) The approximate aggregate percentage of shares of
Common Stock reported beneficially owned by each person
herein is based on 7,749,121 shares outstanding, which is
the total number of shares of Common Stock outstanding as of
April 30, 1996, as reflected in the company's quarterly
report on Form 10-Q filed with the Securities and Exchange
Commission (the "Commission") for the fiscal quarter ended
March 31, 1996 (which is the most recent Form 10-Q on file).
PAGE 13 OF 22 PAGES
<PAGE>
As of the close of business on June 4, 1996:
(i) EGS Associates owns beneficially 54,292 shares of
Common Stock, constituting less than 1% of the shares
outstanding.
(ii) EGS Partners owns directly no shares of Common
Stock. By reason of the provisions of Rule 13D-3 of the
Securities Exchange Act of 1934, as amended (the "Act"), EGS
Partners may be deemed to own beneficially 197,149 shares
purchased for discretionary accounts managed by it, other than
EGS Overseas, constituting approximately 2.54% of the shares
outstanding.
(iii) Bev Partners owns beneficially 32,167 shares
of Common Stock, constituting less than 1% of the shares
outstanding.
(iv) Pharm Fund owns 79,760 shares of Common Stock,
constituting approximately 1.03% of the shares outstanding.
(v) Jonas Partners owns 24,480 shares of Common Stock,
constituting less than 1% of the shares outstanding.
(vi) FK Trading owns 19,862 shares of Common Stock,
constituting less than 1% of the shares outstanding.
(vii) Mr. Greenberg owns beneficially through
ownership by a member of his immediate family, 5,000 shares of
Common Stock, constituting less than 1% of the shares
outstanding.
(viii) Mr. Ketcher owns directly 5,000 shares of
Common Stock, constituting less than 1% of the shares
outstanding.
(ix) Messrs. Ehrman, Gerstl and McLaren own
directly no shares of Common Stock.
By reason of the provisions of Rule 13D-3 of the Act,
each of the General Partners may be deemed to own the 54,292
shares beneficially owned by EGS Associates, the 197,149 shares
beneficially owned by EGS Partners, the 32,167 shares
beneficially owned by Bev Partners, the 79,760 shares
beneficially owned by Pharm Fund, the 24,480 shares beneficially
owned by Jonas Partners, and the 19,862 shares beneficially owned
by FK Trading. When the shares beneficially owned by EGS
Associates, EGS Partners, Bev Partners, Pharm Fund, Jonas
Partners, and FK Trading are aggregated, they total 407,710
shares of Common Stock, constituting approximately 5.26% of the
shares outstanding.
(viii) In the aggregate, the Reporting Persons
beneficially own a total of 506,525 shares of Common Stock,
constituting approximately 5.39% of the shares outstanding.
(b) (i) Each of EGS Associates, EGS Partners (with
respect to shares of EGS Overseas and other discretionary
accounts), Bev Partners, Jonas Partners, Pharm Fund and FK
Trading has the power to vote and to dispose of the shares of
Common Stock beneficially owned by it, which power may be
exercised by the General Partners. Each of EGS Overseas and the
discretionary accounts is a party to an investment management
agreement with EGS Partners pursuant to which EGS Partners has
investment authority with respect to securities held in such
account.
(ii) Mr. Ketcher has the sole power to vote and
dispose of the shares owned directly by him. Mr. Greenberg has
shared power to vote and dispose of the shares owned by a member
of his immediate family.
(c) The trading dates, number of shares of Common
Stock purchased or sold and price per share for all transactions
in the Common Stock from the 60th day prior to May 31, 1996 until
June 4, 1996 by EGS Associates, EGS Partners (excluding EGS
Overseas), EGS Overseas, Pharm Fund, Bev Partners, Jonas
Partners, and FK Trading, are set forth in Schedules A, B, C, D,
E, F, and G, respectively, and were all effected in the over-the-
counter market. During such period, Messrs. Ehrman, Greenberg,
Ketcher, Gerstl, and McLaren, did not enter into any
transactions in the Common Stock.
(d) No person other than each respective record owner
of shares of Common Stock referred to herein is known to have the
right to receive or the power to direct the receipt of dividends
from or the proceeds of sale of such shares of Common Stock.
PAGE 14 OF 22 PAGES
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of our knowledge
and belief, the undersigned certify that the information set
forth in this statement is true, complete and correct.
DATED: June 6, 1996 /s/ William Ehrman
William Ehrman, individually
and as member of EGS PARTNERS,
L.L.C. and as general partner
of each of EGS ASSOCIATES,
L.P., BEV PARTNERS, L.P., THE
PHARMACEUTICAL/MEDICAL
TECHNOLOGY FUND, L.P., JONAS
PARTNERS, L.P., and FK TRADING
PARTNERS, L.P.
/s/ Frederic Greenberg
Frederic Greenberg,
individually and as member of
EGS PARTNERS, L.L.C. and as
general partner of each of
EGS ASSOCIATES, L.P., BEV
PARTNERS, L.P., THE
PHARMACEUTICAL/MEDICAL
TECHNOLOGY FUND, L.P., JONAS
PARTNERS, L.P. and FK TRADING
PARTNERS, L.P.
/s/ Frederick Ketcher
Frederick Ketcher,
individually and as member of
EGS PARTNERS, L.L.C. and as
general partner of each of
EGS ASSOCIATES, L.P., BEV
PARTNERS, L.P., THE
PHARMACEUTICAL/MEDICAL
TECHNOLOGY FUND, L.P., JONAS
PARTNERS, L.P. and FK TRADING
PARTNERS, L.P.
/s/ Jonas Gerstl
Jonas Gerstl, individually and
as member of EGS PARTNERS,
L.L.C. and as general partner
of each of EGS ASSOCIATES,
L.P., BEV PARTNERS, L.P., THE
PHARMACEUTICAL/MEDICAL
TECHNOLOGY FUND, L.P., JONAS
PARTNERS, L.P. and FK TRADING
PARTNERS, L.P.
/s/ James McLaren
James McLaren, individually
and as member of EGS PARTNERS,
L.L.C. and as general partner
of each of EGS ASSOCIATES,
L.P., BEV PARTNERS, L.P., THE
PHARMACEUTICAL/MEDICAL
TECHNOLOGY FUND, L.P., JONAS
PARTNERS, L.P. and FK TRADING
PARTNERS, L.P.
PAGE 15 OF 22 PAGES
<PAGE>
Schedule A
EGS Associates, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
5/29/96 42,372 $5.54
5/30/96 (10,825) $7.01
PAGE 16 OF 22 PAGES
<PAGE>
Schedule B
EGS Partners, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
4/29/96 2,690 $6.98
4/30/96 2,690 $6.63
5/13/96 538 $6.56
5/29/96 137,349 $5.54
5/30/96 (13,597) $7.01
5/31/96 (10,000) $7.32
6/4/96 (10,000) $7.19
PAGE 17 OF 22 PAGES
<PAGE>
Schedule C
EGS Overseas Fund, Ltd.
Transactions in the Common Stock
Price per share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
5/30/96 (760) $7.01
5/31/96 (3,815) $7.32
PAGE 18 OF 22 PAGES
<PAGE>
Schedule D
The Pharmaceutical/Medical Technology Fund, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
4/29/96 7,310 $6.98
4/30/96 7,310 $6.63
5/13/96 1,462 $6.56
5/29/96 21,830 $5.54
5/30/96 (15,903) $6.99
PAGE 19 OF 22 PAGES
<PAGE>
Schedule E
Bev Partners, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
5/29/96 24,212 $5.54
5/30/96 (6,415) $7.01
PAGE 20 OF 22 PAGES
<PAGE>
Schedule F
Jonas Partners, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
5/29/96 20,000 $5.54
5/30/96 (7,500) $6.99
PAGE 21 OF 22 PAGES
<PAGE>
Schedule G
FK Trading Partners, LP
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
4/30/96 15,000 6.63
5/2/96 (15,000) 6.75
5/29/96 19,862 5.54
5/30/96 (5,000) 7.57
5/31/96 (5,000) 7.32
PAGE 22 OF 22 PAGES
